Vertex Pharmaceuticals Current Ratio Growth & History (VRTX)
Vertex Pharmaceuticals's current ratio was 2.90 for fiscal 2025.
View full Vertex Pharmaceuticals company overviewVertex Pharmaceuticals annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 2.90 | 0.21 | +7.75% |
| 2024 | 2024-12-31 | 2.69 | −1.30 | −32.48% |
| 2023 | 2023-12-31 | 3.99 | −0.84 | −17.39% |
| 2022 | 2022-12-31 | 4.83 | 0.36 | +8.14% |
| 2021 | 2021-12-31 | 4.46 | 0.13 | +3.03% |
| 2020 | 2020-12-31 | 4.33 | 0.72 | +19.90% |
| 2019 | 2019-12-31 | 3.61 | 0.18 | +5.32% |
| 2018 | 2018-12-31 | 3.43 | 0.15 | +4.54% |
| 2017 | 2017-12-31 | 3.28 | 0.97 | +41.99% |
| 2016 | 2016-12-31 | 2.31 | −0.47 | −16.87% |
| 2015 | 2015-12-31 | 2.78 | −1.42 | −33.80% |
| 2014 | 2014-12-31 | 4.20 | 0.21 | +5.17% |
| 2013 | 2013-12-31 | 3.99 | 0.32 | +8.68% |
| 2012 | 2012-12-31 | 3.67 | 0.28 | +8.29% |
| 2011 | 2011-12-31 | 3.39 | 1.17 | +52.40% |
| 2010 | 2010-12-31 | 2.23 | −2.36 | −51.47% |
| 2009 | 2009-12-31 | 4.59 | — | — |
Vertex Pharmaceuticals quarterly current ratio
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 3.19 | 0.67 | +26.41% |
| Q1 2026 | 2026-03-31 | 3.02 | 0.38 | +14.26% |
| Q4 2025 | 2025-12-31 | 2.90 | 0.21 | +7.75% |
| Q3 2025 | 2025-09-30 | 2.36 | −0.11 | −4.29% |
| Q2 2025 | 2025-06-30 | 2.52 | −0.00 | −0.04% |
| Q1 2025 | 2025-03-31 | 2.65 | −0.86 | −24.43% |
| Q4 2024 | 2024-12-31 | 2.69 | −1.30 | −32.48% |
| Q3 2024 | 2024-09-30 | 2.47 | −1.62 | −39.56% |
| Q2 2024 | 2024-06-30 | 2.52 | −1.62 | −39.09% |
| Q1 2024 | 2024-03-31 | 3.50 | −0.78 | −18.29% |
| Q4 2023 | 2023-12-31 | 3.99 | −0.84 | −17.39% |
| Q3 2023 | 2023-09-30 | 4.08 | −0.62 | −13.18% |
| Q2 2023 | 2023-06-30 | 4.14 | −0.36 | −8.04% |
| Q1 2023 | 2023-03-31 | 4.28 | −0.47 | −9.85% |
| Q4 2022 | 2022-12-31 | 4.83 | 0.36 | +8.14% |
| Q3 2022 | 2022-09-30 | 4.70 | 0.08 | +1.69% |
| Q2 2022 | 2022-06-30 | 4.50 | −0.11 | −2.28% |
| Q1 2022 | 2022-03-31 | 4.75 | 0.36 | +8.19% |
| Q4 2021 | 2021-12-31 | 4.46 | 0.13 | +3.03% |
| Q3 2021 | 2021-09-30 | 4.62 | 0.90 | +24.26% |
| Q2 2021 | 2021-06-30 | 4.61 | 0.88 | +23.74% |
| Q1 2021 | 2021-03-31 | 4.39 | 0.85 | +24.10% |
| Q4 2020 | 2020-12-31 | 4.33 | 0.72 | +19.90% |
| Q3 2020 | 2020-09-30 | 3.72 | 0.28 | +8.21% |
| Q2 2020 | 2020-06-30 | 3.72 | −0.02 | −0.52% |
| Q1 2020 | 2020-03-31 | 3.54 | −0.24 | −6.38% |
| Q4 2019 | 2019-12-31 | 3.61 | 0.18 | +5.32% |
| Q3 2019 | 2019-09-30 | 3.44 | −0.27 | −7.40% |
| Q2 2019 | 2019-06-30 | 3.74 | 0.07 | +1.81% |
| Q1 2019 | 2019-03-31 | 3.78 | 0.10 | +2.85% |
| Q4 2018 | 2018-12-31 | 3.43 | 0.15 | +4.54% |
| Q3 2018 | 2018-09-30 | 3.71 | 0.44 | +13.40% |
| Q2 2018 | 2018-06-30 | 3.67 | 0.19 | +5.39% |
| Q1 2018 | 2018-03-31 | 3.68 | −0.15 | −3.81% |
| Q4 2017 | 2017-12-31 | 3.28 | 0.97 | +41.99% |
| Q3 2017 | 2017-09-30 | 3.28 | 1.20 | +57.64% |
| Q2 2017 | 2017-06-30 | 3.49 | 1.15 | +49.34% |
| Q1 2017 | 2017-03-31 | 3.82 | 1.28 | +50.39% |
| Q4 2016 | 2016-12-31 | 2.31 | −0.47 | −16.87% |
| Q3 2016 | 2016-09-30 | 2.08 | −1.55 | −42.69% |
| Q2 2016 | 2016-06-30 | 2.33 | −1.13 | −32.59% |
| Q1 2016 | 2016-03-31 | 2.54 | −1.95 | −43.41% |
| Q4 2015 | 2015-12-31 | 2.78 | −1.42 | −33.80% |
| Q3 2015 | 2015-09-30 | 3.63 | −0.81 | −18.22% |
| Q2 2015 | 2015-06-30 | 3.46 | −0.25 | −6.70% |
| Q1 2015 | 2015-03-31 | 4.49 | 0.66 | +17.27% |
| Q4 2014 | 2014-12-31 | 4.20 | 0.21 | +5.17% |
| Q3 2014 | 2014-09-30 | 4.43 | 0.41 | +10.13% |
| Q2 2014 | 2014-06-30 | 3.71 | −0.79 | −17.47% |
| Q1 2014 | 2014-03-31 | 3.83 | −0.01 | −0.30% |
| Q4 2013 | 2013-12-31 | 3.99 | 0.32 | +8.68% |
| Q3 2013 | 2013-09-30 | 4.03 | 0.01 | +0.18% |
| Q2 2013 | 2013-06-30 | 4.50 | 0.30 | +7.19% |
| Q1 2013 | 2013-03-31 | 3.84 | −0.18 | −4.56% |
| Q4 2012 | 2012-12-31 | 3.67 | 0.28 | +8.29% |
| Q3 2012 | 2012-09-30 | 4.02 | 1.75 | +77.08% |
| Q2 2012 | 2012-06-30 | 4.20 | 2.47 | +142.99% |
| Q1 2012 | 2012-03-31 | 4.02 | 1.93 | +91.89% |
| Q4 2011 | 2011-12-31 | 3.39 | 1.17 | +52.40% |
| Q3 2011 | 2011-09-30 | 2.27 | −1.67 | −42.35% |
| Q2 2011 | 2011-06-30 | 1.73 | −1.71 | −49.74% |
| Q1 2011 | 2011-03-31 | 2.10 | −3.23 | −60.62% |
| Q4 2010 | 2010-12-31 | 2.23 | −2.36 | −51.47% |
| Q3 2010 | 2010-09-30 | 3.94 | — | — |
| Q2 2010 | 2010-06-30 | 3.44 | — | — |
| Q1 2010 | 2010-03-31 | 5.33 | — | — |
| Q4 2009 | 2009-12-31 | 4.59 | — | — |
Vertex Pharmaceuticals current ratio trends
Over the last five fiscal years, Vertex Pharmaceuticals's current ratio decreased from 4.33 to 2.90, a change of −1.43. The latest reported quarter, Q2 2026, shows 3.19.
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Vertex Pharmaceuticals source filings ↗